For over a decade, Dr. Mitchell Blutt has served as chief executive officer of Consonance Capital, a health care investment firm based in New York City. Alongside his professional activities, Dr. Mitchell Blutt has dedicated his time and resources to a number of organizations over the years, including the Michael J. Fox Foundation (MJFF).
In a recently released statement, MJFF announced that it is collaborating with the Van Andel Research Institute and the Cure Parkinson’s Trust to assess the effectiveness of nilotinib, a cancer drug that inhibits a protein also associated with Parkinson’s disease. Previous research on nilotinib has shown that the drug is well tolerated and has the potential to improve the motor skills and cognitive function of individuals with Parkinson’s.
As part of the collaboration, MJFF and its partner organizations hope to launch a double-blind, placebo-controlled clinical trial of the drug in 2017. MJFF will host a webinar on nilotinib later this summer and will keep the Parkinson’s community updated on developments through its website and social media channels. For more information, visit www.michaeljfox.org.